Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 65

Similar articles for PubMed (Select 21854308)

1.

Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults.

Ambrose CS.

Expert Rev Vaccines. 2011 Aug;10(8):1127-30. doi: 10.1586/erv.11.101.

PMID:
21854308
2.

Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.

Carter NJ, Curran MP.

Drugs. 2011 Aug 20;71(12):1591-622. doi: 10.2165/11206860-000000000-00000. Review.

PMID:
21861544
3.

Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.

Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM.

J Infect Dis. 2009 Dec 15;200(12):1861-9. doi: 10.1086/648406.

4.

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.

Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD; GRC28 Study Team.

Pediatr Infect Dis J. 2010 Feb;29(2):105-10. doi: 10.1097/INF.0b013e3181b84c34.

PMID:
19934787
5.

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.

Halperin SA, Smith B, Mabrouk T, Germain M, Trépanier P, Hassell T, Treanor J, Gauthier R, Mills EL.

Vaccine. 2002 Jan 15;20(7-8):1240-7.

PMID:
11803087
6.

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S.

Clin Infect Dis. 2010 Nov 1;51(9):997-1004. doi: 10.1086/656578.

7.

Seasonal influenza vaccines.

Fiore AE, Bridges CB, Cox NJ.

Curr Top Microbiol Immunol. 2009;333:43-82. doi: 10.1007/978-3-540-92165-3_3. Review.

PMID:
19768400
8.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.

Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27.

PMID:
19716456
9.

A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.

Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.

Vaccine. 2011 Feb 24;29(10):1921-8. doi: 10.1016/j.vaccine.2010.12.100. Epub 2011 Jan 8.

PMID:
21219987
10.
11.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
14.

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM.

J Infect Dis. 2006 May 1;193(9):1223-8. Epub 2006 Mar 28.

15.

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.

Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M.

Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9.

PMID:
21835220
16.
17.

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.

Hum Vaccin. 2005 Jan-Feb;1(1):37-42. Epub 2005 Jan 12.

PMID:
17038827
18.

Emerging data on the safety and efficacy of influenza vaccines in children.

Vesikari T.

Pediatr Infect Dis J. 2008 Nov;27(11 Suppl):S159-61. doi: 10.1097/INF.0b013e31818a545d.

PMID:
18955892
19.
20.

Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly.

Curran MP, Leroux-Roels I.

Drugs. 2010 Aug 20;70(12):1519-43. doi: 10.2165/11205020-000000000-00000. Review.

PMID:
20687619
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk